CN103830563B - The Chinese medicine composition of preventing and treating chronic hepatitis C and application thereof - Google Patents
The Chinese medicine composition of preventing and treating chronic hepatitis C and application thereof Download PDFInfo
- Publication number
- CN103830563B CN103830563B CN201410077603.1A CN201410077603A CN103830563B CN 103830563 B CN103830563 B CN 103830563B CN 201410077603 A CN201410077603 A CN 201410077603A CN 103830563 B CN103830563 B CN 103830563B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- radix
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of Chinese medicine composition preventing and treating chronic hepatitis C, it is made up of the crude drug of following weight parts: Radix Astragali Preparata 3～120 parts, Rhizoma Atractylodis Macrocephalae (parched) 3～48 parts, Rhizoma Polygonati 3～60 parts, Pulvis Cornus Bubali Concentratus 1～15 part, Herba Scutellariae Barbatae 3～120 parts, Herba Hedyotidis Diffusae 3～120 parts, Radix actinidiae valvatae 3～120 parts, Radix Sophorae Flavescentis 3～40 parts, Rhizoma Corydalis 3～40 parts, Os Sepiae 3～40 parts. Additionally, the invention also discloses the application in the medicine of preparation prevention and treatment chronic hepatitis C of this Chinese medicine composition. Experiments verify that, the Chinese medicine composition of the present invention has prevention and the effect for the treatment of chronic hepatitis C, determined curative effect.
Description
Technical field
The present invention relates to field of medicaments, be specifically related to a kind of Chinese medicine composition, particularly relate to a kind of Chinese medicine composition preventing and treating chronic hepatitis C and application thereof.
Background technology
Chronic hepatitis C is to be infected, by hepatitis C virus (HCV), a kind of infectious disease caused. Whole world HCV infection rate is 3%, and the infected about 1.7 hundred million. China's cri dernier cri disease investigation display, HCV-Ab IgG positive rate is 0.43%, and whole nation HCV infection person has more than 560 ten thousand. After HCV infection, the patient up to 80% can transfer the underlying cause of death that chronic infection, liver cirrhosis and hepatocarcinoma are patients with chronic hepatitis Cs to. Therefore, the preventing and treating of hepatitis C has become serious society and public health problem, is also one of the focal disease in following China's Prevention of Infectious Diseases field.
At present, being called standard regimens by the antiviral therapy scheme that Peg-IFN alpha-2b α combines based on ribavirin, its continued viral response rate (SVR) can reach 44%-66%. But, still suffer from that considerable part patient is not good to this standard regimens response clinically, part response, recurrence etc. after drug withdrawal. Treatment to these patients, modern medicine relies primarily on research and the application of the small-molecule substance of the optimization based on IFN α therapeutic scheme, selectively targeted treatment, and the research even removing interferon therapy is also underway. But, no matter it is optimize treatment or small-molecule substance, is all the treatment based on interferon, and medical expense is higher; And going interferon therapy still in the clinical research of II phase, efficacy and saferry is still still to be tested.
Therefore, hepatitis C is still that a difficult problem for clinical treatment, finds the effective scheme for the treatment of hepatitis C further, is especially suitable for the effective scheme (taking into full account the factors such as curative effect, safety, health economics) of China's national situation, is clinical urgent needs.Chinese medicine, with the individualized treatment advantage of its determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, just day by day demonstrates it unique in the treatment of chronic hepatitis C.
Summary of the invention
The technical problem to be solved in the present invention is in that to provide a kind of Chinese medicine composition preventing and treating chronic hepatitis C and application thereof.
The present invention studies through for many years, develops a kind of Chinese medicine composition preventing and treating chronic hepatitis C, and it, as an organic whole, the ratio better efficacy of single medicinal material, has synergistic function.
Specifically, a first aspect of the present invention there is provided a kind of Chinese medicine composition preventing and treating chronic hepatitis C, and it is made up of the crude drug of following weight parts:
Radix Astragali Preparata 3～120 parts, Rhizoma Atractylodis Macrocephalae (parched) 3～48 parts, Rhizoma Polygonati 3～60 parts, Pulvis Cornus Bubali Concentratus 1～15 part, Herba Scutellariae Barbatae 3～120 parts, Herba Hedyotidis Diffusae 3～120 parts, Radix actinidiae valvatae 3～120 parts, Radix Sophorae Flavescentis 3～40 parts, Rhizoma Corydalis 3～40 parts, Os Sepiae 3～40 parts.
In we, Radix Astragali Preparata, Rhizoma Atractylodis Macrocephalae (parched) are monarch, wherein Radix Astragali Preparata QI invigorating invigorating middle warmer, mend fire supporing yang, let the fire back to its origin, Rhizoma Atractylodis Macrocephalae (parched) invigorating the spleen and benefiting QI, dampness diuretic; Herba Scutellariae Barbatae, Herba Hedyotidis Diffusae, Radix actinidiae valvatae, Radix Sophorae Flavescentis are minister, Herba Scutellariae Barbatae heat-clearing and toxic substances removing, blood circulation promoting and blood stasis dispelling, Herba Hedyotidis Diffusae heat-clearing and toxic substances removing, eliminating carbuncle eliminating stagnation, Radix actinidiae valvatae's heat-clearing and toxic substances removing, Radix Sophorae Flavescentis heat clearing and damp drying, and assistant is with Rhizoma Polygonati boosting qi and nourishing yin, tonifying speen and tonifying kidney; Rhizoma Corydalis promoting blood circulation to remove blood stasis, promoting the circulation of QI to relieve pain, Os Sepiae astringing to arrest bleeding, antacid pain relieving, Pulvis Cornus Bubali Concentratus clearing away heat and cooling blood, arresting convulsion removing toxic substances, full side plays replenishing QI to invigorate the spleen invigorating middle warmer altogether, the effect of heat-clearing and toxic substances removing.
As currently preferred technical scheme, the weight proportion of described each crude drug is:
Radix Astragali Preparata 10～60 parts, Rhizoma Atractylodis Macrocephalae (parched) 6～24 parts, Rhizoma Polygonati 5～30 parts, Pulvis Cornus Bubali Concentratus 2～6 parts, Herba Scutellariae Barbatae 10～60 parts, Herba Hedyotidis Diffusae 10～60 parts, Radix actinidiae valvatae 10～60 parts, Radix Sophorae Flavescentis 5～20 parts, Rhizoma Corydalis 5～20 parts, Os Sepiae 5～20 parts.
As the preferred technical scheme of the present invention, the weight proportion of described each crude drug is:
Radix Astragali Preparata 30 parts, Rhizoma Atractylodis Macrocephalae (parched) 12 parts, Rhizoma Polygonati 15 parts, Pulvis Cornus Bubali Concentratus 3 parts, Herba Scutellariae Barbatae 30 parts, Herba Hedyotidis Diffusae 30 parts, Radix actinidiae valvatae 30 parts, Radix Sophorae Flavescentis 10 parts, Rhizoma Corydalis 10 parts, Os Sepiae 10 parts.
In composition described above, the weight of each crude drug calculates with crude drug, as it is known to those skilled in the art, composition described above is by weight as proportioning, can increase according to corresponding proportion when actual production or reduce, but the constant rate of each single crude drug weight proportion.
The Chinese medicine composition of the present invention can make various oral medicinal herb conventional dose in clinical hepatitis C treatment by the conventional method of this area after direct or extracted processing. Described extraction processing technique, it is possible to use Traditional Chinese medicine extraction method known in those skilled in the art, for instance solvent extraction method, steam distillation, sublimed method and supercritical extraction etc.
Described medicament can be any pharmaceutically useful dosage form, includes but not limited to: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch; Peroral dosage form is preferably used, includes but not limited to: capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum etc. Described oral formulations can contain conventional excipient, such as binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, tablet can be carried out coating if desired. Wherein, suitable filler includes the filler that cellulose, mannitol, lactose are similar with other; Suitable disintegrating agent includes starch, polyvinylpyrrolidone and starch derivatives, for instance sodium starch glycollate; Suitable lubricant includes, for instance magnesium stearate. Suitable wetting agent includes sodium lauryl sulphate etc.
A second aspect of the present invention there is provided the application in the medicine of preparation prevention and treatment chronic hepatitis C of the described Chinese medicine composition.
The results show, the Chinese medicine composition of the present invention rna expression amount than the HCV of each single medicinal material has very significant to reduce (P < 0.01), each single medicinal material is alone increases to some extent than it to point out its antiviral activity, namely the Chinese medicine composition of the present invention has the effect of Synergistic, and result is in Table 1. The Chinese medicine composition combined with westem treatment of the present invention has synergistic corrosion virus effect, and when treating 12 months, hepatitis C virus (HCV) RNA negative conversion rate improves 10.7%, and rate of descent improves 7.2%, and result is in Table 3 and table 4. From table 5 and table 6, Chinese medicine composition of the present invention has good antivirus action, and the Chinese medicine composition combined with westem treatment of the present invention has synergistic corrosion virus effect, and when treating 6 months, HCVRNA negative conversion rate improves 7.34%. Compared by liver puncture pathological section it can be seen that by after the traditional Chinese medicine composition for treating of the present invention, the pathological state of experimenter's hepatic tissue has clear improvement (see Fig. 1). Above the results show Chinese medicine composition of the present invention has prevention and the effect for the treatment of chronic hepatitis C, determined curative effect.
The details of various aspects of the present invention will be able to detailed description in chapters and sections subsequently. By hereafter and the description of claim, the feature of the present invention, purpose and advantage will become apparent from.
Accompanying drawing explanation
Fig. 1 a and Fig. 1 b is hepatic tissue pathology section statining figure (× 200) before and after the traditional Chinese medicine composition for treating of the employing present invention of the embodiment of the present invention 9; Wherein, Fig. 1 a is the pathological section figure (amplifying 200 times) of hepatic tissue before treatment; Fig. 1 b is the pathological section figure (amplifying 200 times) of hepatic tissue after treating 12 months.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is expanded on further. Should be understood that these embodiments are merely to illustrate the present invention rather than restriction the scope of the present invention. The experimental technique of unreceipted actual conditions in the following example, generally conventionally condition or according to manufacturer it is proposed that condition. Unless otherwise indicated, otherwise all of percent, ratio, ratio or number be by weight.
Unless otherwise defined, the same meaning that all specialties used in literary composition are familiar with one skilled in the art with scientific words. Additionally, any method similar or impartial to described content and material all can be applicable in the inventive method. The use that preferably implementation described in literary composition and material only present a demonstration.
The features described above that the present invention mentions, or the feature that embodiment is mentioned can be in any combination. The disclosed all features of patent specification can with any composition forms use, each feature disclosed in description, it is possible to any alternative characteristics providing identical, impartial or similar purpose replaces. Therefore except having special instruction, disclosed feature to be only impartial or similar features general example.
Embodiment 1:
Crude drug is taken by following weight proportion:
Radix Astragali Preparata 3 grams, Rhizoma Atractylodis Macrocephalae (parched) 3 grams, Rhizoma Polygonati 3 grams, Pulvis Cornus Bubali Concentratus 1 gram, Herba Scutellariae Barbatae 3 grams, Herba Hedyotidis Diffusae 3 grams, Radix actinidiae valvatae 3 grams, Radix Sophorae Flavescentis 3 grams, Rhizoma Corydalis 3 grams, Os Sepiae 3 grams.
Above ten taste crude drug are pulverized respectively and mix, and make pulverulent mixture, then make honeyed pill by the conventional method of this area, every honeyed pill 3 grams, oral 2 times of every day, each 2.
Embodiment 2:
Crude drug is taken by following weight proportion:
Radix Astragali Preparata 10 grams, Rhizoma Atractylodis Macrocephalae (parched) 6 grams, Rhizoma Polygonati 5 grams, Pulvis Cornus Bubali Concentratus 2 grams, Herba Scutellariae Barbatae 10 grams, Herba Hedyotidis Diffusae 10 grams, Radix actinidiae valvatae 10 grams, Radix Sophorae Flavescentis 5 grams, Rhizoma Corydalis 5 grams, Os Sepiae 5 grams.
Above ten taste crude drug boiling 2 times, from boiling timing, each 1 hour, first time adds 10 times amount water, and second time adds 8 times amount water, after decoction, merge twice decoction liquor, let cool 3000rpm centrifugal 10 minutes, remove supernatant, it is concentrated into the extractum that proportion is 1.35, adds appropriate dextrin and Icing Sugar, dried in 70 DEG C, make granule granulation agent, to obtain final product, pack, 10 grams every bag, oral 3 times of every day, each 1 bag.
Embodiment 3:
Crude drug is taken by following weight proportion:
Radix Astragali Preparata 30g, Rhizoma Atractylodis Macrocephalae (parched) 12g, Rhizoma Polygonati 15g, Pulvis Cornus Bubali Concentratus 3g, Herba Scutellariae Barbatae 30g, Herba Hedyotidis Diffusae 30g, Radix actinidiae valvatae 30g, Radix Sophorae Flavescentis 10g, Rhizoma Corydalis 10g, Os Sepiae 10g.
Above ten taste crude drug add suitable quantity of water and decoct 2 times, from boiling timing, each 1 hour, after decoction, merge twice decoction liquor, and instructions of taking is: in one day, a point secondary is taken.
Embodiment 4:
Crude drug is taken by following weight proportion:
Radix Astragali Preparata 60 grams, Rhizoma Atractylodis Macrocephalae (parched) 24 grams, Rhizoma Polygonati 30 grams, Pulvis Cornus Bubali Concentratus 6 grams, Herba Scutellariae Barbatae 60 grams, Herba Hedyotidis Diffusae 60 grams, Radix actinidiae valvatae 60 grams, Radix Sophorae Flavescentis 20 grams, Rhizoma Corydalis 20 grams, Os Sepiae 20 grams.
Above ten taste crude drug boiling 2 times, from boiling timing, each 1 hour, first time adds 10 times amount water, and second time adds 8 times amount water, after decoction, merge twice decoction liquor, let cool 3000rpm centrifugal 10 minutes, remove supernatant, be concentrated into into dry cream, tablet is made again by the conventional method of this area, every 0.5 gram, oral 3 times of every day, each 3.
Embodiment 5:
Crude drug is taken by following weight proportion:
Radix Astragali Preparata 120 grams, Rhizoma Atractylodis Macrocephalae (parched) 48 grams, Rhizoma Polygonati 60 grams, Pulvis Cornus Bubali Concentratus 15 grams, Herba Scutellariae Barbatae 120 grams, Herba Hedyotidis Diffusae 120 grams, Radix actinidiae valvatae 120 grams, Radix Sophorae Flavescentis 40 grams, Rhizoma Corydalis 40 grams, Os Sepiae 40 grams.
Add 70% alcohol reflux 2 times, from boiling timing, each 1 hour, first time adds 6 times amount ethanol, and second time adds 4 times amount ethanol, after decoction, merging twice decoction liquor, after filtration, decompression is reduced to without ethanol, spray drying again, get dry extract powder, then makes capsule, every capsules 0.5 gram by the conventional method of this area, oral 3 times of every day, each 3.
Embodiment 6: the comparative study of Chinese medicine composition single medicinal material each with it In Vitro Anti hepatitis C virus curative effect of the present invention
Crude drug is taken by the weight proportion of embodiment 3, add suitable quantity of water to decoct 2 times, from boiling timing, each 1 hour, after decoction, merge twice decoction liquor, concentrating under reduced pressure, lyophilization is to lyophilized powder again, standby as composition freeze-dried powder (ZHW), other each single medicinal material takes in compositions to be measured accordingly, same preparation method of mixture, lyophilized powder is made after decocting and concentrating, respectively Radix Astragali Preparata lyophilized powder (ZHQ), Rhizoma Atractylodis Macrocephalae (parched) lyophilized powder (CBZ), Rhizoma Polygonati lyophilized powder (HJ), Pulvis Cornus Bubali Concentratus lyophilized powder (SNJ), Herba Scutellariae Barbatae lyophilized powder (BZL), Herba Hedyotidis Diffusae lyophilized powder (SSC), Radix actinidiae valvatae's lyophilized powder (MRS), Radix Sophorae Flavescentis lyophilized powder (KS), Rhizoma Corydalis lyophilized powder (YHS) and Os Sepiae lyophilized powder (WZG), standby.
External chimera hepatitis c virus infection Huh7.5 cell is adopted to carry out the antivirus action screening of each component. Dimethyl sulfoxide DMSO is adopted to be configured to the mother solution of 200mg/ml above-mentioned each lyophilized powder standby, it is diluted to corresponding concentration according to experiment needs during experiment, another by the hepatitis c virus infection normal Secondary Culture of Huh7.5 cell, the Huh7.5 cell of trophophase of taking the logarithm makes 1 × 105The cell suspension of individual/ml, in 24welldish, every hole adds the cell suspension of 500 μ l, shakes up, and puts to 37 DEG C of 5%CO2In incubator, cultivate 12h, cell conditioned medium liquid in 24welldish is inhaled and abandons 100 μ l, respectively take in the cell that the 100 each lyophilized powder medicinal liquids of μ l join corresponding concentration labelling, shake up, put into 37 DEG C of 5%CO2After middle continuation is cultivated 12 hours, extracting HCVRNA, set the amount of virus after adopting pcr amplification, during experiment, adopt interferon-' alpha ' (IFN-α) as positive drug control experiment.
Test result indicate that, compare with normal control and have significant differences, the Chinese medicine composition of the present invention is substantially less than Normal group, and the rna expression amount of HCV (hepatitis C virus) is 30.4 ± 2.9 (P < 0.01), points out it to have obvious anti-hepatitis C virus effect; Compare with its each single medicinal material, the Chinese medicine composition of the present invention rna expression amount than the HCV of each single medicinal material has very significant to reduce (P < 0.01), each single medicinal material is alone increases to some extent than it to point out its antiviral activity, and namely the Chinese medicine composition of the present invention has the effect of Synergistic. Result is in Table 1.
The impact on HCVRNA relative expression quantity in cell of the table 1. each extract freeze-drying powder
(except positive drug, each medicine is 50 μ g/ml)
Note:**Compare with normal control and have significant differences, P < 0.01;##Compare with ZHW and have significant differences, P < 0.01.
Embodiment 7: the Chinese medicine composition In Vitro Anti hepatitis C virus comparative study of the different ratio of the present invention
The lyophilized powder (respectively compound recipe A, Compound B, compound recipe C, compound recipe D and compound recipe E) of the Chinese medicine composition of the present invention that crude drug is made is taken as experimental subject using the weight proportion by embodiment 1～5, according to the method for embodiment 6, adopt the antivirus action of the different compounds of the external chimera hepatitis c virus infection Huh7.5 cell investigation present invention.
Test result indicate that, comparing with normal control has significant differences, and the different compound recipe groups of the present invention are substantially less than Normal group, and there was no significant difference between each group. Result, in Table 2, the In Vitro Anti hepatitis C virus best results of compound recipe C, namely proves that the weight proportion of embodiment 3 is optimum.
The impact on HCVRNA relative expression quantity in cell of the lyophilized powder of the different compound recipe of table 2.
(except positive drug, each medicine is 50 μ g/ml)
Note:**Compare with normal control and have significant differences,
Embodiment 8: Chinese medicine composition associating PEG-IFN alpha-2a (Peg-IFN alpha-2b the a-2a)+ribavirin therapy chronic hepatitis C of the present invention
In order to show the clinical efficacy of the Chinese medicine composition of the present invention, we adopt multicenter, random, double blinding, placebo-controlled study method, research is divided into treatment group (PEG-IFN alpha-2a+ribavirin+Chinese medicine composition of the present invention) and matched group (PEG-IFN alpha-2a+ribavirin+traditional Chinese medicine placebo), treatment 24-48 week. Treatment group and matched group, according to the ratio of 1:1, are produced the table of random numbers by the simulation of SAS statistical package, include exclusion standard according to research approach and enter to organize case, and experimenter, according to the priority including research in, sequentially enters treatment group and matched group by random number sequence number. Treatment group: PEG-IFN alpha-2a (offer of Roche Holding Ag of Switzerland), 180 μ g, subcutaneous injection, once in a week. Ribavirin (Sichuan U.S. greatly healthy Pharmaceutical provide), 900mg divided three times and was administered orally every day, morning, noon and afternoon each 300mg. Chinese medicine compound is (by Radix Astragali Preparata 30g, Rhizoma Atractylodis Macrocephalae (parched) 12g, Rhizoma Polygonati 15g, Pulvis Cornus Bubali Concentratus 3g, Herba Scutellariae Barbatae 30g, Herba Hedyotidis Diffusae 30g, Radix actinidiae valvatae 30g, Radix Sophorae Flavescentis 10g, Rhizoma Corydalis 10g, Os Sepiae 10g, the Chinese medicine granules being made up of three nine-day periods after the winter solstice pharmacy), every day 1 dose, twice daily. Matched group: Peg-IFN alpha-2b, 180ug, subcutaneous injection, once in a week. Ribavirin, every day 900mg divide three times be administered orally, morning, noon and afternoon each 300mg. Traditional Chinese medicine placebo (identical with the outward appearance of test drug, packaging (except mark) and consumption, mainly it is made up of dextrin, starch, Icing Sugar and is mixed colours by food coloring again; By three nine-day periods after the winter solstice, pharmaceutical Co. Ltd provides), every day 1 dose, drink after brewing, twice daily.
Experimental result: from table 3 and table 4, therapy of combining Chinese and Western medicine scheme has synergistic corrosion virus effect, and when treating 12 months, hepatitis C virus (HCV) RNA negative conversion rate improves 10.7%, and rate of descent improves 7.2%.
Table 3. HCVRNA negative conversion rate
The table 4. HCVRNA rate of descent ratio of 2log (decline >)
Embodiment 9: the intractable chronic hepatitis C of traditional Chinese medicine composition for treating of the present invention
Adopting multicenter, random, double blinding, placebo-controlled study method, research is divided into treatment group (Chinese medicine composition of the present invention) and matched group (PEG-IFN alpha-2a+ribavirin+traditional Chinese medicine placebo), treats 24～48 weeks. Treatment group and matched group, according to the ratio of 1:1, are produced the table of random numbers by the simulation of SAS statistical package, include exclusion standard according to research approach and enter to organize case, and experimenter, according to the priority including research in, sequentially enters treatment group and matched group by random number sequence number. Treatment group: Chinese medicine compound is (by Radix Astragali Preparata 30g, Rhizoma Atractylodis Macrocephalae (parched) 12g, Rhizoma Polygonati 15g, Pulvis Cornus Bubali Concentratus 3g, Herba Scutellariae Barbatae 30g, Herba Hedyotidis Diffusae 30g, Radix actinidiae valvatae 30g, Radix Sophorae Flavescentis 10g, Rhizoma Corydalis 10g, Os Sepiae 10g form, the Chinese medicine granules being made up of three nine-day periods after the winter solstice pharmacy), every day 1 dose, twice daily. Matched group: Peg-IFN alpha-2b, 180 μ g, subcutaneous injection, once in a week. Ribavirin, every day 900mg divide three times be administered orally, morning, noon and afternoon each 300mg. Traditional Chinese medicine placebo (identical with the outward appearance of test drug, packaging (except mark) and consumption, mainly it is made up of dextrin, starch, Icing Sugar and is mixed colours by food coloring again; By three nine-day periods after the winter solstice, pharmaceutical Co. Ltd provides), every day 1 dose, drink after brewing, twice daily.
Experimental result: from table 5 and table 6, traditional Chinese medical therapeutic program has good antivirus action, and when treating 6 months, HCVRNA negative conversion rate improves 7.34%. Compared it can be seen that by after the traditional Chinese medicine composition for treating of the present invention, it (is the pathological section figure of the front hepatic tissue for the treatment of see Fig. 1 a and Fig. 1 b, Fig. 1 a that the pathological state of experimenter's hepatic tissue has clear improvement by liver puncture pathological section; Fig. 1 b is the pathological section figure of hepatic tissue after treating 12 months).
Table 5. HCVRNA negative conversion rate
The table 6. HCVRNA rate of descent ratio of 2log (decline >)
Many aspects involved in the present invention have been done as explained above. However, it should be understood that put before not necessarily departing from spirit of the present invention, it can be carried out equivalent change and modification by those skilled in the art, and described change and modification fall into the coverage of the application claims equally.
Claims (5)
1. the Chinese medicine composition preventing and treating chronic hepatitis C, it is characterised in that it is made up of the crude drug of following weight parts:
Radix Astragali Preparata 3～120 parts, Rhizoma Atractylodis Macrocephalae (parched) 3～48 parts, Rhizoma Polygonati 3～60 parts, Pulvis Cornus Bubali Concentratus 1～15 part, Herba Scutellariae Barbatae 3～120 parts, Herba Hedyotidis Diffusae 3～120 parts, Radix actinidiae valvatae 3～120 parts, Radix Sophorae Flavescentis 3～40 parts, Rhizoma Corydalis 3～40 parts, Os Sepiae 3～40 parts.
2. by the Chinese medicine composition described in claim 1, it is characterized in that, the weight portion scope of described crude drug is: Radix Astragali Preparata 10～60 parts, Rhizoma Atractylodis Macrocephalae (parched) 6～24 parts, Rhizoma Polygonati 5～30 parts, Pulvis Cornus Bubali Concentratus 2～6 parts, Herba Scutellariae Barbatae 10～60 parts, Herba Hedyotidis Diffusae 10～60 parts, Radix actinidiae valvatae 10～60 parts, Radix Sophorae Flavescentis 5～20 parts, Rhizoma Corydalis 5～20 parts, Os Sepiae 5～20 parts.
3. by the Chinese medicine composition described in claim 1, it is characterized in that, the weight of described crude drug is: Radix Astragali Preparata 30 parts, Rhizoma Atractylodis Macrocephalae (parched) 12 parts, Rhizoma Polygonati 15 parts, Pulvis Cornus Bubali Concentratus 3 parts, Herba Scutellariae Barbatae 30 parts, Herba Hedyotidis Diffusae 30 parts, Radix actinidiae valvatae 30 parts, Radix Sophorae Flavescentis 10 parts, Rhizoma Corydalis 10 parts, Os Sepiae 10 parts.
4. by the Chinese medicine composition described in claim 1, it is characterised in that described Chinese medicine composition makes oral medicinal herb preparation.
5. the application preventing by the Chinese medicine composition described in any one of claim 1-3 in preparation and treating in the medicine of chronic hepatitis C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410077603.1A CN103830563B (en) | 2014-03-05 | 2014-03-05 | The Chinese medicine composition of preventing and treating chronic hepatitis C and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410077603.1A CN103830563B (en) | 2014-03-05 | 2014-03-05 | The Chinese medicine composition of preventing and treating chronic hepatitis C and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103830563A CN103830563A (en) | 2014-06-04 |
| CN103830563B true CN103830563B (en) | 2016-06-15 |
Family
ID=50794665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410077603.1A Expired - Fee Related CN103830563B (en) | 2014-03-05 | 2014-03-05 | The Chinese medicine composition of preventing and treating chronic hepatitis C and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103830563B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1113779A (en) * | 1994-06-17 | 1995-12-27 | 殷广全 | Anti- hepatitis B preparation |
| CN1706474A (en) * | 2005-05-29 | 2005-12-14 | 王福山 | Chinese medicine composition for treating hepatitis B and viral hepatitis |
-
2014
- 2014-03-05 CN CN201410077603.1A patent/CN103830563B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1113779A (en) * | 1994-06-17 | 1995-12-27 | 殷广全 | Anti- hepatitis B preparation |
| CN1706474A (en) * | 2005-05-29 | 2005-12-14 | 王福山 | Chinese medicine composition for treating hepatitis B and viral hepatitis |
Non-Patent Citations (3)
| Title |
|---|
| "慢性丙型病毒性肝炎证候规律及中西医结合治疗方案的研究"研究方案;聂红明等;《中西医结合学报》;20110415;第09卷(第04期);第365-373页 * |
| 丙型肝炎证治概述;焦一鸣等;《实用中医药杂志》;20020315;第18卷(第03期);第52页 * |
| 清肝冲剂治疗慢性丙型肝炎的研究;孙学华等;《上海中医药杂志》;20030515;第37卷(第05期);第20-22页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103830563A (en) | 2014-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6455078B1 (en) | Medicinal herbal composition for treating liver diseases and HIV | |
| WO2011113190A1 (en) | Pharmaceutical composition for treating aids and preparation method thereof | |
| CN111803583A (en) | Antiviral traditional Chinese medicine composition, preparation method and application thereof | |
| CN103223069A (en) | Traditional Chinese medicine composition for treating hepatitis | |
| CN103933195B (en) | A kind of Chinese medicine composition and preparation prevent and treat the application in hepatopathy medicine | |
| CN101390970B (en) | Traditional Chinese medicine for treating hepatitis B and preparation method thereof | |
| CN104771589A (en) | Traditional Chinese medicine composition for treating fatty liver and application thereof | |
| CN103830563B (en) | The Chinese medicine composition of preventing and treating chronic hepatitis C and application thereof | |
| CN101904935A (en) | Chinese medicinal composition for improving immunity of organisms, tonifying middle-jiao and qi and treating canine distemper | |
| CN101199806A (en) | Drug for treating laxness, preparing method and quality controlling method thereof | |
| CN105477465A (en) | Chinese herb preparation with liver protection function and preparing technology of Chinese herb preparation | |
| CN102068674A (en) | Chinese medicinal composition for treating chronic diarrhea and preparation method thereof | |
| CN101618156A (en) | Medicine composition for treating hepatitis B and preparation method thereof | |
| CN101057906B (en) | Traditional Chinese medicinal composition for treating hepatitis and its pharmaceutical preparation and application | |
| CN106265913A (en) | A kind of pharmaceutical composition containing monoammonium glycyrrhizinate and its preparation method and application | |
| CN107019740A (en) | It is a kind of to be used to prevent and treat Chinese medicine composition of virus B hepatitis and preparation method thereof | |
| CN101491574A (en) | Traditional Chinese medicine compound recipe for treating chronic hepatitis-B and preparation method thereof | |
| CN102125590B (en) | Ginsenoside Rg1-containing pseudo-ginseng active ingredient as well as preparation method and application thereof | |
| CN102475778B (en) | Preparation method for traditional Chinese medicinal composition used for treating essential hypertension | |
| CN103893368B (en) | The celestial clever Radix Rehmanniae compositions of Sugarless type and granule thereof and method for making | |
| CN102475781B (en) | Method for preparing traditional Chinese medicine composition used for treating essential hypertension | |
| CN102475779B (en) | Preparation method of traditional Chinese medicine composition for treating primary hypertension | |
| CN102475784B (en) | Chinese medicinal composition for treating essential hypertension and its preparation method | |
| CN102475785B (en) | Preparation method of Chinese medicinal composition for treating essential hypertension | |
| CN1969924B (en) | Pharmaceutical composition of Silibinin and isatis root |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160615 Termination date: 20190305 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |